Valproic Acid
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB00313 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 31 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | trigeminal nerve neoplasm | KG + DL |
| 2 | visual epilepsy | KG + DL |
| 3 | trigeminal neuralgia | KG + DL |
| 4 | orgasm-induced seizures | KG + DL |
| 5 | micturation-induced seizures | KG + DL |
| 6 | startle epilepsy | KG + DL |
| 7 | thinking seizures | KG + DL |
| 8 | audiogenic seizures | KG + DL |
| 9 | eating seizures | KG + DL |
| 10 | reading seizures | KG + DL |
| 11 | trichotillomania | KG + DL |
| 12 | Tourette syndrome | KG + DL |
| 13 | beta-ketothiolase deficiency | KG + DL |
| 14 | status epilepticus | KG + DL |
| 15 | Rett syndrome, congenital variant | KG + DL |
| 16 | 14q12 microdeletion syndrome | KG + DL |
| 17 | epilepsy with generalized tonic-clonic seizures | KG + DL |
| 18 | adolescent/adult onset autosomal dominant epilepsy with auditory features | KG + DL |
| 19 | partial motor epilepsy | KG + DL |
| 20 | myoclonic-atonic epilepsy | KG + DL |
| 21 | attention deficit-hyperactivity disorder | KG + DL |
| 22 | familial mesial temporal lobe epilepsy with febrile seizures | KG + DL |
| 23 | partial epilepsy | KG + DL |
| 24 | faciodigitogenital syndrome | KG + DL |
| 25 | electroclinical syndrome | KG + DL |
| 26 | attention deficit hyperactivity disorder, inattentive type | KG + DL |
| 27 | epilepsy, childhood absence, susceptibility to | KG + DL |
| 28 | early onset absence epilepsy | KG + DL |
| 29 | chondromyxoid fibroma | KG + DL |
| 30 | facial neuralgia | KG + DL |
| 31 | specific developmental disorder | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.